From the secondary analysis, the less conservative but clinically meaningful criterion of secure response (defined for a 50% or more reduction in MADRS from baseline for two weeks) was used. In the patients who attained secure response, twenty five.8% during the esketamine group and 57.six% within the placebo group relapsed, https://edwardy233ynd2.bloggerswise.com/profile